within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CA03_Butobarbital;

model Butobarbital
  extends Pharmacolibrary.Drugs.ATC.N.N05CA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N05CA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Butobarbital is a barbiturate derivative with sedative and hypnotic properties. It was historically used for the short-term treatment of insomnia and as a premedication for anesthesia but is now largely obsolete due to the availability of safer alternatives. It is not widely approved or used in contemporary clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical adult following oral administration, as no direct human PK study data could be found in the literature.</p><h4>References</h4><ol><li><p>Cheymol, G, et al., &amp; Portet, R (1979). Study of urinary excretion of butobarbitone in man in relation to the percentage of ideal body weight. <i>British journal of clinical pharmacology</i> 7(3) 303–309. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1979.tb00937.x\">10.1111/j.1365-2125.1979.tb00937.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34416/\">https://pubmed.ncbi.nlm.nih.gov/34416</a></p></li><li><p>Grove, J, et al., &amp; Williams, FM (1974). Butobarbitone metabolism in man: identification of 3&#x27;-ketobutobarbitone. <i>The Journal of pharmacy and pharmacology</i> 26(3) 175–178. DOI:<a href=\"https://doi.org/10.1111/j.2042-7158.1974.tb09250.x\">10.1111/j.2042-7158.1974.tb09250.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4151075/\">https://pubmed.ncbi.nlm.nih.gov/4151075</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Butobarbital;
